Conference and Expo Singles Product Out for Innovation for Second
Time in Three Years; Recognizes Product's Role in Enhanced
Capabilities for Detection and Evaluation of Safety Signals at
GlaxoSmithKline (GSK)
WALTHAM, Mass.--(BUSINESS WIRE)--May 15, 2008--Phase Forward
(NASDAQ: PFWD), a leading provider of data management solutions for
clinical trials and drug safety, today announced that its Lincoln
Safety Group's Clinical Trials Signal Detection (CTSD(TM)) product
garnered a prestigious "Best Practices" award at the recent Bio-IT
World Life Sciences Conference and Expo in Boston. Today's
announcement marks the second time in three years CTSD has been
honored by the conference and expo; in 2006, CTSD took home a Best of
Show award.
As in 2006, the 2008 award was given to CTSD in the "Clinical
Trials and Research" category. This year's award recognizes the CTSD
implementation at GlaxoSmithKline. GSK partnered with the Phase
Forward Lincoln Safety Group in 2006 and collaborated with Lincoln's
development team to design a Safety Review interface which enhances
Clinical Safety users' ability to review data from both completed and
ongoing studies. The Safety Review interface combined with CTSD's
automated screening on adverse events, laboratory, vital signs and
electrocardiogram (ECG) data can help facilitate timely detection and
evaluation of safety signals.
"We are gratified by the recognition Bio-IT World Life Sciences
Conference and Expo has again given our CTSD product," said Phase
Forward Lincoln Safety Group President Chan Russell. "We congratulate
our co-recipient GSK for their innovative use of CTSD."
"We are honored once again to be in the spotlight at Bio-IT World.
In 2005, GSK and the Lincoln Safety Group won the award for our
post-marketing safety signal detection tool and we said we would be
back with a clinical trial signal detection system," said Trevor
Gibbs, GSK's Senior Vice-President, Medical Governance and
Pharmacovigilance. "This award is nicely aligned with GSK's deployment
of the CTSD tool. We look forward to continuing our successful
partnership with the Lincoln Safety Group."
Bio-IT World is an industry-leading publication addressing the
technologies driving discovery, development and clinical trials.
Bio-IT World's Best Practices Awards Program, established in 2003,
recognizes teams for their novel and innovative uses of technology to
improve the efficiency and economics of R&D, drug discovery, and
clinical research and trials. The quality and breadth of the 2008
program is underscored by the record 54 entries. For more information
on Bio-IT World, please visit: www.bio-itworld.com. For more
information on The Life Sciences Conference and Expo, please visit:
http://www.bio-itworldexpo.com/.
About Bio-IT World, Inc.
Bio-IT World (www.bio-itworld.com), the flagship publication of
Cambridge Healthtech Institute (CHI), is the leading source of news on
technology and strategic innovation in drug discovery, development,
and clinical trials. Bio-IT World explores the tools and results of
predictive biology as the industry adapts to the new world of
personalized medicine. Bio-IT World has won 34 national and regional
awards, more than any other magazine covering the life sciences
industry. CHI offers a suite of published resources through a new
division--Cambridge Healthtech Media Group--that includes Bio-IT World
magazine, numerous topic-specific eNewsletters, white papers,
webcasts, podcasts, conferences, and the Bio-IT World Best Practices
Awards. The magazine is based in Needham, MA.
About Phase Forward
Phase Forward is a leading provider of integrated data management
solutions for clinical trials and drug safety. The company offers
proven solutions for electronic data capture (InForm(TM)), phase I
clinic automation (LabPas(TM)), clinical data management
(Clintrial(TM)), clinical trials signal detection (CTSD(TM)),
strategic pharmacovigilance (WebVDME(TM) and Signal Management),
adverse event reporting (Empirica(TM) Trace) and applied data
standards (WebSDM(TM)). In addition, the company provides services in
the areas of application implementation, hosting and validation, data
integration, business process optimization, safety data management and
industry standards. Phase Forward's products and services have been
utilized in over 10,000 clinical trials involving more than 1,000,000
clinical trial study participants at over 280 organizations and
regulatory agencies worldwide including: AstraZeneca, Boston
Scientific, Dana-Farber Cancer Institute, Eli Lilly, the U.S. Food and
Drug Administration, GlaxoSmithKline, Harvard Clinical Research
Institute, Merck Serono, Novartis, Novo Nordisk, PAREXEL
International, Procter & Gamble, Quintiles, sanofi-aventis,
Schering-Plough Research Institute, Servier, Tibotec and the U.K.
Medicines and Healthcare Products Regulatory Agency. Additional
information about Phase Forward is available at www.phaseforward.com.
Cautionary Statement
Certain statements made in this press release that are not based
on historical information are forward-looking statements which are
made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. This press release contains express or
implied forward-looking statements relating to, among other things,
the performance and features of Phase Forward's products and services,
future business and operations plans of a Phase Forward customer, and
the ability of Phase Forward's customers to realize benefits from the
use of Phase Forward's products and services. These statements are
neither promises nor guarantees, but are subject to a variety of risks
and uncertainties, many of which are beyond Phase Forward's control,
which could cause actual results to differ materially from those
contemplated in these forward-looking statements. In particular, the
risks and uncertainties include, among other things, the ability of
Phase Forward's customers to realize benefits from the use of its
products and services, changes in regulatory requirements applicable
to Phase Forward's customers and the manner in which they conduct
business, changes in commonly used industry standards, the possibility
that customers' needs or plans may change over time, and competition.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
the date hereof. Phase Forward undertakes no obligation to update or
revise the information contained in this press release, whether as a
result of new information, future events or circumstances or
otherwise. For additional disclosure regarding these and other risks
faced by Phase Forward, see the disclosure contained in Phase
Forward's public filings with the Securities and Exchange Commission
including, without limitation, its most recent Annual Report on Form
10-K.
CONTACT: Phase Forward
Amy Dall, 781-902-4683
amy.dall@phaseforward.com
or
CHEN PR, Inc.
Randy Wambold, 781-672-3119
rwambold@chenpr.com
SOURCE: Phase Forward
